(Updates the headline and first paragraph with latest company filing.)
Novavax (NVAX) said Wednesday it is still awaiting a decision from the US Food and Drug Administration on its biologics license application for its Covid vaccine.
The vaccine approval is in limbo after the FDA missed a deadline, but a decision could be any day, The Wall Street Journal reported earlier.
The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a full approval, the report said, citing sources.
FDA did not immediately respond to requests for comment from MT Newswires.
NVAX shares were up 3% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.